Clinical Trial Update: Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 pilot trial evaluating intralesional ranibizumab for pterygium, assessing vascularity, size, and recurrence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pterygium

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Universiti Sains Malaysia | Conditions: Pterygium | Phase 2, Phase 3 | Status: COMPLETED